What Cannabis Cannabinoids Reduce Nighttime Agitation in Dementia? 

Nighttime agitation is a common and challenging symptom in dementia, leading to poor sleep and increased caregiver burden. As interest in cannabis-based treatments rises, many are asking whether certain cannabinoids could help reduce this form of agitation. Specifically, CBD (cannabidiol) and THC (tetrahydrocannabinol) have been explored for their potential to reduce nighttime agitation in dementia patients. 

What The Research Shows 

The non-psychoactive nature of CBD makes it a promising option for dementia care, particularly as it may help reduce agitation and improve sleep without the cognitive impairment associated with THC.  

A 2020 study published in Frontiers in Pharmacology found that CBD helped reduce agitation and sleep disturbances in patients with Alzheimer’s disease without significant side effects. Similarly, a 2019 study in The Lancet demonstrated that cannabis extracts with a balanced CBD-to-THC ratio were effective in reducing nighttime restlessness in dementia patients. While THC can be useful for sleep, it can also cause confusion and cognitive decline in some patients. Research on the optimal use of THC in dementia care is still limited.  

What The Guidelines Say 

NICE (National Institute for Health and Care Excellence) advises against prescribing cannabis-based products for dementia-related agitation outside of clinical trials. According to NICE NG144, evidence for cannabis in dementia is insufficient to support routine use. 

The NHS also does not approve cannabis products for dementia. While some cannabis-based treatments are licensed for conditions like multiple sclerosis, they are not authorised for use in dementia. 

Expert Commentary 

The Alzheimer’s Society states that while CBD shows promise, cannabinoid use in dementia should be carefully monitored, with more evidence needed. The Royal College of Psychiatrists also cautions that cannabis treatments should only be used in carefully controlled trials to assess their safety and effectiveness. 

Clinical Bottom Line 

• CBD shows potential for reducing nighttime agitation and improving sleep in dementia without significant cognitive side effects. 

• Low doses of THC combined with CBD may also be effective but come with psychoactive side effects in some cases. 

• NICE and NHS guidelines recommend that cannabis be used only within clinical trials for dementia symptoms. 

• More research is needed to confirm the long-term safety and efficacy of cannabinoid-based treatments. 

About AlleviMed 

If you are considering whether medical cannabis could be appropriate for a loved one with dementia, AlleviMed offers private eligibility consultations across the UK. The service connects families with GMC-registered specialists for safe, compliant advice on evidence-based cannabis treatments. You can learn more at allevimed.co.uk once the site is live. 

Takeaway 

CBD-rich cannabis products offer promise for reducing nighttime agitation in dementia, but the evidence is still inconclusive. While low doses of THC may be effective, the risk of psychoactive side effects remains a concern. NICE and NHS guidelines recommend cannabis use only in clinical trials, pending more research on its safety and efficacy.